XIPERE (triamcinolone acetonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 4h ago · AI intelligence enriched 10h ago
XIPERE is a triamcinolone acetonide suspension administered by injection, a corticosteroid hormone receptor agonist used to treat inflammatory conditions. It works by binding to corticosteroid receptors to suppress immune and inflammatory responses. The product was approved in October 2021 and is currently in peak commercial lifecycle.
Product is at peak commercial maturity with 13.6 years of exclusivity remaining, suggesting stable commercial teams focused on market penetration and indication expansion.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Worked on XIPERE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on XIPERE offers stability within a competitive-advantage position backed by strong patent protection through 2040. Career growth is driven by commercial execution, market penetration, and indication expansion rather than clinical pipeline advancement, making this suitable for brand-building, field sales, and market access professionals.